Are you, or do you know someone working on breakthrough biomedical translational research?
The New York City Investment Fund (NYCIF), with assistance of New York City Economic Development Corporation (NYCEDC) is sponsoring the BioAccelerate NYC Prize, a citywide competition that will provide funding for biomedical translational research. The focus is technology and research that have advanced beyond the point where an academic institution or the National Institutes of Health (NIH) is prepared to fund, but before the investment and commercial sectors are interested in committing dollars.
The BioAccelerate NYC judges are expected to award between three and five winners who will each receive up to $250,000 in the form of a grant with participation. A condition of funding is that serious efforts are made to locate any associated spin out company in New York City.
The BioAccelerate NYC competition is looking to fund translational research related to therapeutics, devices and diagnostics that can direct clinical care. As a key part of its evaluation, BioAccelerate NYC will consider the commercial market potential, specifically: 1) whether the technology would be able to attract venture or other commercial capital, assuming this translational funding produced positive results; and 2) whether the technology could support the growth of an independent enterprise over time. Some of the target activities include:
- Medicinal chemistry/early toxicology work
- Screening to produce reference compounds
- Support to move research from in vitro to in vivo
For more info, visit: http://bit.ly/aFAVi5
N.B.: Initial proposals are due by Wednesday, September 1, 2010
Frank Rimalovski | Managing Director
NYU Innovation Venture Fund
[address removed] | +1 [masked]